Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis

Exclusion Criteria

• •Recent DVT (less than 2 months) objectively proven by venous ultrasound - Severe ilio-femoral DVT requiring recanalization
• •Duration of treatment of more than 24 h since diagnosis
• •Patients with acute symptoms (leg pain and swelling) for more than 5 days
• •Planned surgery in the following 3 weeks, impossible to postpone
• •Active haemorrhage or high risk of haemorrhage
• •Symptoms of Post Thrombotic Syndrome
• •Active neoplasm
• •APL syndrome
• •Renal insufficiency (Creatinine clearance (Cockcroft-Gault) \<20 mL/min)
• •Hepatic disease / or Hepatic Insufficiency / or serious liver disease
• •Hyperkaliemia more than 5 mmol/L
• •Patients with mechanical prosthetic heart valve
• •weight more than 105 kgs in order to avoid difficulties with a dosage of 20000UI OF TINZAPARIN Any anti-inflammatory drugs or anti-platelet therapy
• •Any other concomitant anticoagulant treatment such as VKA, heparin, fondaparinux and direct oral anticoagulants
• •Contraindications to tinzaparin according to their SmPC
• •Patient with asthma, If patients need to receive tinzaparin 10000UI antiX-a/0.5ml for the study,(due to sodium metabisulfite in the solution)
• •Pregnant women or breastfeeding
• •patient with age under 18
• •Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)